Design, synthesis and in vitro/in vivo evaluation of orally bioavailable prodrugs of a catechol-O-methyltransferase inhibitor

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 8, 2010, Pages 2614-2616

  Rautio, Jarkko ^a   Leppänen, Jukka ^a   Lehtonen, Marko ^a   Laine, Krista ^a   Koskinen, Mikko ^b   Pystynen, Jarmo ^b   Savolainen, Jouko ^c   Sairanen, Mikko ^b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b ORION CORPORATION   (Finland)

^c Fennopharma Ltd   (Finland)

Author keywords

COMT inhibitor; Oral bioavailability; Prodrug

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; PRODRUG;

ARTICLE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CATECHOL O-METHYLTRANSFERASE; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MALE; PRODRUGS; RATS; RATS, WISTAR;

RATTUS;

EID: 77950053525     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.02.057     Document Type: Article

References (26)

1. Forno L.S. J. Neuropathol. Exp. Neurol. 55 (1996) 259
2. Lewitt P.A. N. Engl. J. Med. 359 (2008) 2468
3. Seeberger L.C., and Hauser R.A. Expert Rev. Neurother. 9 (2009) 929
4. Heikkinen H., Saraheimo M., Antila S., Ottoila P., and Pentikainen P.J. Eur. J. Clin. Pharmacol. 56 (2001) 821
5. Beaumont K., Webster R., Gardner I., and Dack K. Curr. Drug Metab. 4 (2003) 461
6. Rautio J., Kumpulainen H., Heimbach T., Oliyai R., Oh D., Jarvinen T., and Savolainen J. Nat. Rev. Drug Disc. 7 (2008) 255
7. Sakamoto F., Ikeda S., and Tsukamoto G. Chem. Pharm. Bull. (Tokyo) 32 (1984) 2241
8. Iyer R.P., Yu D., Ho N., and Agrawal S. Synth. Commun. 25 (1995) 2739
9. Ouyang H., Vander Velde D.G., Borchardt R.T., and Siahaan T.J. J. Pept. Res. 59 (2002) 183
10. Liederer B.M., and Borchardt R.T. J. Pharm. Sci. 95 (2006) 1177
11. Ehrnebo M., Nilsson S.O., and Boreus L.O. J. Pharmacokinet. Biopharm. 7 (1979) 429
12. Todd P.A., and Heel R.C. Drugs 31 (1986) 198
13. Noble S., and Goa K.L. Drugs 58 (1999) 479
14. Lyseng-Williamson K.A., Reynolds N.A., and Plosker G.L. Drugs 65 (2005) 413
15. Speit G., Schutz P., and Merk O. Mutagenesis 15 (2000) 85
16. DeGoey D.A., Grampovnik D.J., Flosi W.J., Marsh K.C., Wang X.C., Klein L.L., McDaniel K.F., Liu Y., Long M.A., Kati W.M., Molla A., and Kempf D.J. J. Med. Chem. 52 (2009) 2964
17. Li F., Maag H., and Alfredson T. J. Pharm. Sci. 97 (2008) 1109
18. Perkins E.J., and Abraham T. Drug Metab. Dispos. 35 (2007) 1903
19. Warner G.T., and Jarvis B. Drugs 62 (2002) 1345
20. Sum Z.M., Sefton A.M., Jepson A.P., and Williams J.D. J. Antimicrob. Chemother. 23 (1989) 861
21. Tougou K., Nakamura A., Watanabe S., Okuyama Y., and Morino A. Drug Metab. Dispos. 26 (1998) 355
22. Biggadike K., Angell R.M., Burgess C.M., Farrell R.M., Hancock A.P., Harker A.J., Irving W.R., Ioannou C., Procopiou P.A., Shaw R.E., Solanke Y.E., Singh O.M., Snowden M.A., Stubbs R.J., Walton S., and Weston H.E. J. Med. Chem. 43 (2000) 19
23. Kurkela M., Siiskonen A., Finel M., Tammela P., Taskinen J., and Vuorela P. Anal. Biochem. 331 (2004) 198
24. Lundstrom K., Tilgmann C., Peranen J., Kalkkinen N., and Ulmanen I. Biochim. Biophys. Acta 1129 (1992) 149
25. Haasio K., Koponen A., Penttila K.E., and Nissinen E. Eur. J. Pharmacol. 453 (2002) 21
26. Haasio K., Nissinen E., Sopanen L., and Heinonen E.H. J. Neural. Trans. 109 (2002) 1391